Anti-tumor agent containing cytarabine, anti- tumor effect enhancing agent which is used in combination with cytarabine, anti-tumor kit, and anti-tumor agent which is used in combination with cytarabine
AssigneeFUJIFILM Corporation
InventorsSatoshi Kitazawa, Yukiko Ishii, Koichi Saito, Shun Matsuda
Life of this patent
Estimating the term…
Abstract
An object of the present invention is to provide a combination drug containing cytarabine and a DHODH inhibitor, as a new anti-tumor agent, and to provide an anti-tumor effect enhancing agent which is used in combination with cytarabine, an anti-tumor kit, and an anti-tumor agent which is used in combination with cytarabine. According to the present invention, an anti-tumor agent and an anti-tumor kit containing cytarabine and a dihydroorotate dehydrogenase inhibitor compound are provided.
Claims5
A method for treating a tumor, including administering cytarabine and a dihydroorotate dehydrogenase inhibitor compound to a subject,
- wherein the tumor cells are cytarabine-resistant leukemia cells;
- and
- the dihydroorotate dehydrogenase inhibitor compound is at least one or more compounds selected from the group consisting of Brequinar, Vidofludimus, Teriflunomide, Leflunomide, N-(2-chloro-6-fluorophenyl)-4-[4-ethyl-3-(hydroxymethyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-5-fluoro-2-{[(2 S)-1,1,1-trifluoropropan-2-yl] oxy} benzamide, (S)-4-chlorophenyl 6-chloro-1-(4-hydroxyphenyl)-3,4-dihydro-1H-pyrido[3,4-b]indol-2 (9H)-carboxylate, and a compound represented by General Formula (1), or a salt thereof,
- in the formula,
- G1 is a CH or nitrogen atom;
- R1 is a hydrogen atom, a halogen atom, a C1-6 alkyl group which may be substituted, or a C3-8 cycloalkyl group which may be substituted;
- and
- R2 is an aryl group which may be substituted or a bicyclic heterocyclic group which may be substituted, or
- the dihydroorotate dehydrogenase inhibitor compound is at least one or more compounds selected from the group consisting of ASLAN003 (2-((3,5-difluoro-3′-methoxybiphenyl-4-yl)amino) nicotinic acid) and 5-cyclopropyl-2-((1-phenyl-1H-indol-5-yl)amino) nicotinic acid, or a salt thereof.
A method for enhancing an anti-tumor effect, including administering a dihydroorotate dehydrogenase inhibitor compound to a subject in combination with cytarabine,
- wherein the tumor cells are cytarabine-resistant leukemia cells;
- and
- the dihydroorotate dehydrogenase inhibitor compound is at least one or more compounds selected from the group consisting of Brequinar, Vidofludimus, Teriflunomide, Leflunomide, N-(2-chloro-6-fluorophenyl)-4-[4-ethyl-3-(hydroxymethyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-5-fluoro-2-{[(2S)-1,1,1-trifluoropropan-2-yl]oxy} benzamide, (S)-4-chlorophenyl 6-chloro-1-(4-hydroxyphenyl)-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-carboxylate, and a compound represented by General Formula (1), or a salt thereof,
- in the formula,
- G1 is a CH or nitrogen atom;
- R1 is a hydrogen atom, a halogen atom, a C1-6 alkyl group which may be substituted, or a C3-8 cycloalkyl group which may be substituted;
- and
- R2 is an aryl group which may be substituted or a bicyclic heterocyclic group which may be substituted, or
- the dihydroorotate dehydrogenase inhibitor compound is at least one or more compounds selected from the group consisting of ASLAN003 (2-((3,5-difluoro-3′-methoxybiphenyl-4-yl)amino) nicotinic acid) and 5-cyclopropyl-2-((1-phenyl-1H-indol-5-yl)amino) nicotinic acid, or a salt thereof.
Dependencies are inferred from the claim text.